Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 26Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Lung Neoplasms 6Uterine Cervical Neoplasms 5Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasms 3Liposarcoma, Myxoid 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Radiation Injuries 2Neurofibrosarcoma 2Neoplasm Metastasis 2Melanoma 2Lymphatic Metastasis 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Cholangiocarcinoma 2

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × Radiation Dose Hypofractionation × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

NRG Oncology

Phase 3 Recruiting
486 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡